These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 27166590)

  • 21. Perspectives on chemotherapy for the management of double-hit lymphoma.
    Al-Juhaishi T; Mckay J; Sindel A; Yazbeck V
    Expert Opin Pharmacother; 2020 Apr; 21(6):653-661. PubMed ID: 32066288
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetics and diffuse large B-Cell lymphoma.
    Niroula R; Butera J
    R I Med J (2013); 2015 Nov; 98(11):23-6. PubMed ID: 26517251
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.
    Wang W; Hu S; Lu X; Young KH; Medeiros LJ
    Am J Surg Pathol; 2015 Aug; 39(8):1132-9. PubMed ID: 25828391
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patients with double/triple copy number gains on C-MYC, BCL2, and/or BCL6 treated with standard chemotherapy have a similarly poor prognosis than those with high-grade B cell lymphoma with C-MYC and BCL2 and/or BCL6 rearrangements: a single-center experience on a consecutive cohort of large B cell lymphomas.
    Willenbacher E; Willenbacher W; Weger R; Dominik W; Manzl C; Brunner A
    Ann Hematol; 2020 Sep; 99(9):2125-2132. PubMed ID: 32613279
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.
    Landsburg DJ; Falkiewicz MK; Petrich AM; Chu BA; Behdad A; Li S; Medeiros LJ; Cassaday RD; Reddy NM; Bast MA; Vose JM; Kruczek KR; Smith SE; Patel P; Hernandez-Ilizaliturri F; Karmali R; Rajguru S; Yang DT; Maly JJ; Blum KA; Zhao W; Vanslambrouck C; Nabhan C
    Br J Haematol; 2016 Nov; 175(4):631-640. PubMed ID: 27469075
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging Strategies in Treating Double Hit Lymphomas.
    Nabhan C; Mato AR
    Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):563-568. PubMed ID: 28711572
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-grade B-cell Lymphoma With MYC Rearrangement and Without BCL2 and BCL6 Rearrangements Is Associated With High P53 Expression and a Poor Prognosis.
    Li S; Weiss VL; Wang XJ; Desai PA; Hu S; Yin CC; Tang G; Reddy NM; Medeiros LJ; Lin P
    Am J Surg Pathol; 2016 Feb; 40(2):253-61. PubMed ID: 26448193
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EBV
    Liu H; Xu-Monette ZY; Tang G; Wang W; Kim Y; Yuan J; Li Y; Chen W; Li Y; Fedoriw GY; Zhu F; Fang X; Luedke C; Medeiros LJ; Young KH; Hu S
    Histopathology; 2022 Feb; 80(3):575-588. PubMed ID: 34637146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
    Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
    Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MYC/BCL2 double-hit high-grade B-cell lymphoma.
    Li S; Lin P; Young KH; Kanagal-Shamanna R; Yin CC; Medeiros LJ
    Adv Anat Pathol; 2013 Sep; 20(5):315-26. PubMed ID: 23939148
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Unexpected favorable outcome in a patient with high grade B-cell lymphoma with abnormalities of MYC, BCL6 and BCL2 loci.
    Adams T; Fuchs D; Shadoan PK; Johnstone L; Lau BM; McGhan L; Anwer F; Al-Kateb H
    Cancer Genet; 2018 Apr; 222-223():25-31. PubMed ID: 29666005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnosis of 'double hit' diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC.
    Swerdlow SH
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):90-9. PubMed ID: 25696840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas.
    Sarkozy C; Traverse-Glehen A; Coiffier B
    Lancet Oncol; 2015 Nov; 16(15):e555-e567. PubMed ID: 26545844
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Double-hit and triple-hit lymphomas arising from follicular lymphoma following acquisition of MYC: report of two cases and literature review.
    Xu X; Zhang L; Wang Y; Zhang Q; Zhang L; Sun B; Zhang Y
    Int J Clin Exp Pathol; 2013; 6(4):788-94. PubMed ID: 23573328
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hitting back at lymphoma: How do modern diagnostics identify high-risk diffuse large B-cell lymphoma subsets and alter treatment?
    Abramson JS
    Cancer; 2019 Sep; 125(18):3111-3120. PubMed ID: 31287161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concurrent inhibition of MYC and BCL2 is a potentially effective treatment strategy for double hit and triple hit B-cell lymphomas.
    Cinar M; Rosenfelt F; Rokhsar S; Lopategui J; Pillai R; Cervania M; Pao A; Cinar B; Alkan S
    Leuk Res; 2015 Jul; 39(7):730-8. PubMed ID: 25916698
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma.
    Sermer D; Bobillo S; Dogan A; Zhang Y; Seshan V; Lavery JA; Batlevi C; Caron P; Hamilton A; Hamlin P; Horwitz S; Joffe E; Kumar A; Matasar M; Noy A; Owens C; Moskowitz A; Palomba ML; Straus D; von Keudell G; Rodriguez-Rivera I; Falchi L; Zelenetz A; Yahalom J; Younes A
    Blood Adv; 2020 Jul; 4(14):3382-3390. PubMed ID: 32722781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tailoring front-line therapy in diffuse large B-cell lymphoma: who should we treat differently?
    Davies A
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):284-294. PubMed ID: 29222268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary Cutaneous Diffuse Large B-Cell Lymphoma With a MYC-IGH Rearrangement and Gain of BCL2: Expanding the Spectrum of MYC/BCL2 Double-Hit Lymphomas.
    Testo N; Olson LC; Subramaniyam S; Hanson T; Magro CM
    Am J Dermatopathol; 2016 Oct; 38(10):769-74. PubMed ID: 27391453
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome.
    Caponetti GC; Dave BJ; Perry AM; Smith LM; Jain S; Meyer PN; Bast M; Bierman PJ; Bociek RG; Vose JM; Armitage JO; Aoun P; Fu K; Greiner TC; Chan WC; Sanger WG; Weisenburger DD
    Leuk Lymphoma; 2015; 56(11):3082-9. PubMed ID: 25827211
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.